Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).

Phase 2 Active not recruiting 86 enrolled Ausper Biopharma Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

AB-10-8003 is a randomized, multi-center phase II study to evaluate the efficacy and safety of AHB-137 in subjects with HBeAg-negative CHB under stable NA treatment.

Timeline

Start: 2024-07-10
Primary completion: 2025-05-26
Completion: 2026-10-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AHB-137	Antisense oligonucleotide	—	Subcutaneous

Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).

Summary

Timeline

Drugs

Indications